ReviewNature reviews. Rheumatology2012
The pathogenesis, diagnosis and treatment of Raynaud phenomenon.
Review in Nature reviews. Rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03984422 (Development of an Application for the Monitoring and Evaluation of Raynaud's Phenomenon), which is not on this map. Cited by 101 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of an Application for the Monitoring and Evaluation of Raynaud's Phenomenon
Who cites it
101 citing papers in PubMed, 3 syntheses or guidelines pooled it, 292 citations in OpenAlex.
- Pooled it
- Peripheral vasoconstriction induced by β-adrenoceptor blockers: a systematic review and a network meta-analysis.British journal of clinical pharmacology · 2016Pooled it
- Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.British journal of clinical pharmacology · 2016Pooled it
- A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's.Rheumatology (Oxford, England) · 2023Trial
- Spurious Fingertip Oxygen Desaturation During the 6-Minute Walk Test in a Patient With NSIP and Raynaud Phenomenon: The Value of Forehead Pulse Oximetry and Transcutaneous Oxygen Tension.Respirology case reports · 2026Article
- Drug-Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Proceedings of the 2Mediterranean journal of rheumatology · 2026Article
- Beyond Raynaud's: Atypical Peripheral Vascular Manifestations in a Case of CREST Syndrome.Clinical case reports · 2026Article
- Factors associated with diagnostic delay and specialty consultation patterns in systemic sclerosis: A cross-sectional study.Rheumatology international · 2025Article
- The N-of-1 Trials and where to use them in Rheumatology.Mediterranean journal of rheumatology · 2025Review
- Cold responses and hormonal echoes: a comprehensive view of Raynaud's vascular dysfunction.Inflammopharmacology · 2025Review
- Systemic Sclerosis Presenting as Osteomyelitis of the Finger: Physicians Must Maintain a High Index of Suspicion for Systemic Sclerosis when Evaluating Patients with Fingertip Ulceration or Infection.Journal of orthopaedic case reports · 2025Article
- Sudden Hand Color Changes in a Young Man.Oman medical journal · 2025Article
- Knockdown of LncRNA MEG3 promotes damage of vascular endothelial cells induced by vibration.Scientific reports · 2025Article
- Unveiling the Enigma: Idiopathic Digital Infarction-A Case Report and Literature Review.Clinical case reports · 2025Article
- Infrared thermography for the diagnosis and monitoring of Raynaud's phenomenon: current evidence and future directions.Reumatologia · 2025Review
- Article
- Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy.Biomarker research · 2024Review
- Effect of betablockers on the course of Martorell hypertensive ulcers: a retrospective study.Acta dermato-venereologica · 2024Article
- Genetic and functional analysis of Raynaud's syndrome implicates loci in vasculature and immunity.Cell genomics · 2024Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past 10 years have seen the publication of results from several multicentre clinical trials in primary and systemic sclerosis (SSc)-related Raynaud phenomenon. The publication of these studies has occurred as a result of new insights into the pathogenesis of Raynaud phenomenon, which are directing new treatment approaches, and increased international collaboration between clinicians and scientists. Although the pathogenesis of Raynaud phenomenon is complex, abnormalities of the blood vessel wall, of neural control mechanisms and of intravascular (circulating) factors are known to interact and contribute. Key players relevant in drug development include nitric oxide, endothelin-1, alpha adrenergic receptor activation, abnormal signal transduction in vascular smooth muscle, oxidative stress and platelet activation. The main advances in diagnosis have been a clearer understanding of autoantibodies and of abnormal nailfold capillary patterns as independent predictors of SSc, and widespread use and increased availability of capillaroscopy. The ultimate aim is to translate the advances made in the pathophysiology and early diagnosis into development of treatments to prevent and reverse digital vascular dysfunction and injury. This Review provides an update of the pathogenesis, diagnosis and treatment of Raynaud phenomenon. Current and future treatment approaches are discussed, and some key unanswered questions are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.